Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRVS Corvus Pharmaceuticals	$3.80	$3.40	$1.75 ▼ $10.00	$257.68M	0.67	736,845 shs	509,024 shs
FHTX Foghorn Therapeutics	$4.14 -4.2%	$3.94	$2.94 ▼ $10.25	$230.77M	3.13	141,311 shs	388,693 shs
MGX Metagenomi	$1.69 -5.0%	$1.56	$1.23 ▼ $6.90	$63.19M	-0.65	793,826 shs	260,689 shs
OCGN Ocugen	$0.84 +1.2%	$0.73	$0.52 ▼ $1.98	$246.56M	4.21	4.49 million shs	2.94 million shs

5G Stocks: The Path Forward is Profitable

Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRVS Corvus Pharmaceuticals	0.00%	+8.88%	+7.95%	-5.94%	+80.95%
FHTX Foghorn Therapeutics	0.00%	0.00%	-0.48%	-14.64%	-26.47%
MGX Metagenomi	0.00%	+4.34%	+13.44%	-17.55%	-73.59%
OCGN Ocugen	0.00%	-9.29%	+14.39%	+29.55%	-48.20%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRVS Corvus Pharmaceuticals	2.1969 of 5 stars	3.5	1.0	2.4	2.5	0.6
FHTX Foghorn Therapeutics	2.3779 of 5 stars	3.6	2.0	2.7	1.7	0.6
MGX Metagenomi	2.2737 of 5 stars	3.5	3.0	2.6	0.0	0.0
OCGN Ocugen	0.8901 of 5 stars	3.5	0.0	1.6	0.0	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRVS Corvus Pharmaceuticals	3.00	Buy	$15.00	294.74% Upside
FHTX Foghorn Therapeutics	3.13	Buy	$12.13	192.87% Upside
MGX Metagenomi	3.00	Buy	$13.00	669.09% Upside
OCGN Ocugen	3.00	Buy	$6.00	610.65% Upside

Current Analyst Ratings Breakdown

Latest MGX, CRVS, FHTX, and OCGN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	CRVS Corvus Pharmaceuticals	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Outperform ➝ Outperform	$12.00 ➝ $11.00
5/15/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
5/15/2025	MGX Metagenomi	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$13.00 ➝ $12.00
5/14/2025	MGX Metagenomi	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight	$20.00 ➝ $16.00
5/14/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy
5/12/2025	OCGN Ocugen	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$8.00 ➝ $7.00
5/12/2025	OCGN Ocugen	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$7.00 ➝ $7.00
5/9/2025	CRVS Corvus Pharmaceuticals	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$15.00 ➝ $17.00
4/30/2025	FHTX Foghorn Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$9.00 ➝ $9.00
4/30/2025	FHTX Foghorn Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$13.00 ➝ $13.00
4/23/2025	FHTX Foghorn Therapeutics	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform

(Data available from 6/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	$0.79 per share	N/A
FHTX Foghorn Therapeutics	$23.50M	9.82	N/A	N/A	($1.83) per share	-2.26
MGX Metagenomi	$45.26M	1.40	N/A	N/A	N/A	∞
OCGN Ocugen	$4.52M	54.52	N/A	N/A	$0.16 per share	5.28

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRVS Corvus Pharmaceuticals	-$27.03M	-$0.98	N/A	N/A	N/A	N/A	-70.71%	-45.90%	8/12/2025 (Estimated)
FHTX Foghorn Therapeutics	-$98.43M	-$1.36	N/A	N/A	N/A	-357.53%	N/A	-30.98%	8/7/2025 (Estimated)
MGX Metagenomi	-$68.25M	-$2.11	N/A	N/A	N/A	-134.27%	-43.23%	-18.86%	8/13/2025 (Estimated)
OCGN Ocugen	-$63.08M	-$0.19	N/A	N/A	N/A	-532.51%	-154.75%	-90.79%	8/14/2025 (Estimated)

Latest MGX, CRVS, FHTX, and OCGN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	FHTX Foghorn Therapeutics	-$0.30	-$0.30	N/A	-$0.30	$4.96 million	$5.95 million
5/13/2025	Q1 2025	MGX Metagenomi	-$0.62	-$0.68	-$0.06	-$0.68	$8.75 million	$4.13 million
5/9/2025	Q1 2025	OCGN Ocugen	-$0.06	-$0.05	+$0.01	-$0.05	N/A	$1.48 million
5/8/2025	Q1 2025	CRVS Corvus Pharmaceuticals	-$0.13	-$0.13	N/A	-$0.13	N/A	N/A
3/25/2025	Q4 2024	CRVS Corvus Pharmaceuticals	-$0.12	-$0.18	-$0.06	-$0.18	N/A	N/A
3/17/2025	Q4 2024	MGX Metagenomi	-$0.62	-$0.63	-$0.01	-$0.63	$13.18 million	$9.61 million
3/6/2025	Q4 2024	FHTX Foghorn Therapeutics	-$0.43	-$0.30	+$0.13	-$0.30	$8.56 million	$2.86 million
3/5/2025	Q4 2024	OCGN Ocugen	-$0.05	-$0.05	N/A	-$0.05	$0.30 million	$0.76 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRVS Corvus Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
FHTX Foghorn Therapeutics	N/A	N/A	N/A	N/A	N/A
MGX Metagenomi	N/A	N/A	N/A	N/A	N/A
OCGN Ocugen	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRVS Corvus Pharmaceuticals	N/A	0.92	0.92
FHTX Foghorn Therapeutics	N/A	4.77	4.77
MGX Metagenomi	N/A	6.18	6.18
OCGN Ocugen	0.04	2.58	2.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRVS Corvus Pharmaceuticals	46.64%
FHTX Foghorn Therapeutics	61.55%
MGX Metagenomi	N/A
OCGN Ocugen	10.27%

Insider Ownership

Company	Insider Ownership
CRVS Corvus Pharmaceuticals	28.50%
FHTX Foghorn Therapeutics	7.58%
MGX Metagenomi	N/A
OCGN Ocugen	4.42%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRVS Corvus Pharmaceuticals	30	68.17 million	44.15 million	Optionable
FHTX Foghorn Therapeutics	120	55.74 million	50.57 million	Optionable
MGX Metagenomi	236	37.38 million	N/A	N/A
OCGN Ocugen	80	292.03 million	278.82 million	Optionable

MGX, CRVS, FHTX, and OCGN Headlines

Recent News About These Companies

Jane Street Group LLC Purchases 357,891 Shares of Ocugen, Inc. (NASDAQ:OCGN)

June 1 at 3:14 AM | marketbeat.com

Ocugen’s OCU410ST receives Rare Pediatric Disease Designation for the treatment of ABCA4-associated retinopathies

May 27, 2025 | ophthalmologytimes.com

Ocugen wins FDA rare pediatric disease status for genetic eye disorder treatment

May 27, 2025 | msn.com

Ocugen, Inc. Receives FDA Rare Pediatric Disease Designation for OCU410ST in Treatment of ABCA4-Associated Retinopathies

May 27, 2025 | quiverquant.com

Ocugen Announces Rare Pediatric Disease Designation Granted for OCU410ST—Modifier Gene Therapy for the Treatment of Stargardt Disease

May 27, 2025 | globenewswire.com

Noble Financial Predicts Ocugen's Q2 Earnings (NASDAQ:OCGN)

May 16, 2025 | marketbeat.com

The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 14, 2025 | nasdaq.com

Ocugen (NASDAQ:OCGN) Price Target Cut to $7.00 by Analysts at HC Wainwright

May 14, 2025 | marketbeat.com

Ocugen's (OCGN) "Buy" Rating Reiterated at Chardan Capital

May 14, 2025 | marketbeat.com

Ocugen (NASDAQ:OCGN) Releases Earnings Results, Beats Estimates By $0.01 EPS

May 13, 2025 | marketbeat.com

Ocugen Reports Progress in Q1 2025 with Advancements in Gene Therapy

May 13, 2025 | msn.com

1OCGN : The Analyst Verdict: Ocugen In The Eyes Of 5 Experts

May 13, 2025 | benzinga.com

Ocugen, Inc. (NASDAQ:OCGN) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Ocugen Stock Rises On Better-Than-Feared Q1 Loss: Retail Turns Bullish

May 9, 2025 | msn.com

Ocugen, Inc. (OCGN) Q1 2025 Earnings Call Transcript

May 9, 2025 | seekingalpha.com

Ocugen Provides Business Update with First Quarter 2025 Financial Results

May 9, 2025 | globenewswire.com

A Look at Ocugen's Upcoming Earnings Report

May 9, 2025 | benzinga.com

Ocugen (OCGN) Projected to Post Earnings on Friday

May 6, 2025 | marketbeat.com

Ocugen to Host Q1 2025 Earnings Call and Business Update on May 9

May 5, 2025 | msn.com

OCUGEN Earnings Preview: Recent $OCGN Insider Trading, Hedge Fund Activity, and More

May 2, 2025 | nasdaq.com

Ocugen to Host Conference Call on Friday, May 9 at 8:30 A.M. ET to Discuss Business Updates and First Quarter 2025 Financial Results

May 2, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MGX, CRVS, FHTX, and OCGN Company Descriptions

Corvus Pharmaceuticals NASDAQ:CRVS

$3.80 0.00 (0.00%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$3.79 -0.01 (-0.26%)

As of 05/30/2025 06:18 PM Eastern

Corvus Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis. The company is also developing ciforadenant (CPI-444), an oral small molecule antagonist of the A2A receptor that is in Phase 2 clinical trial for the treatment of metastatic renal cell cancer; and mupadolimab (CPI-006), a humanized monoclonal antibody, which is in Phase 1b clinical trial for the treatment of non-small cell lung cancer and head and neck cancer. In addition, it is developing CPI-182, an antibody designed to block inflammation and myeloid suppression that is in investigational new drug application-enabling studies, as well as CPI-935, an adenosine A2B receptor antagonist to prevent fibrosis. Corvus Pharmaceuticals, Inc. has a license afreemnt with Monash University to research, develop, and commercialize certain antibodies directed to CXCR2 for the treatment of human diseases; and Vernalis (R&D) Limited to develop, manufacture, and commercialize products containing certain adenosine receptor antagonists, including ciforadenant, as well as strategic collaboration with Angel Pharmaceuticals Co. Ltd. for the development and commercialization of mupadolimab. Corvus Pharmaceuticals, Inc. was incorporated in 2014 and is based in Burlingame, California.

Foghorn Therapeutics NASDAQ:FHTX

$4.14 -0.18 (-4.17%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$4.08 -0.06 (-1.45%)

As of 05/30/2025 04:04 PM Eastern

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States. The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system. It develops FHD-286, a small molecule inhibitor of the enzymatic activity of BRG1 and BRM that is in phase I for the treatment of relapsed and/or refractory acute myeloid leukemia/myelodysplastic syndrome. The company is also developing therapies for mutant cancers, such as Non-Small Cell Lung, bladder, endometrial, colorectal, and melanoma cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma. It has a research collaboration and license agreement with Merck Sharp & Dohme Corp. to discover and develop novel oncology therapeutics against a transcription factor target; and Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM. Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Metagenomi NASDAQ:MGX

$1.69 -0.09 (-5.04%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$1.70 +0.01 (+0.87%)

As of 05/30/2025 07:52 PM Eastern

Metagenomi, Inc., a genetic medicines company, develops therapeutics for patients using metagenomics-derived genome editing toolbox in the United States. The company's genome editing toolbox includes programmable nucleases, base editors, and RNA and DNA-mediated integration systems, such as prime editing systems and clustered regularly interspaced short palindromic repeat-associated transposases. It has a strategic collaboration and license agreement with ModernaTX, Inc. focusing on new genome editing system for in vivo human therapeutic applications; a development, option, and license agreement with Affini-T Therapeutics, Inc. to develop and commercialize gene edited T-cell receptor-based therapeutic products in the field of treatment, prevention, or diagnosis of human cancer; and a collaboration and license agreement with Ionis Pharmaceuticals, Inc. to research, develop, and commercialize investigational medicines using genome editing technologies. The company was incorporated in 2016 and is based in Emeryville, California.

Ocugen NASDAQ:OCGN

$0.84 +0.01 (+1.21%)

Closing price 05/30/2025 04:00 PM Eastern

Extended Trading

$0.84 -0.01 (-0.63%)

As of 05/30/2025 07:59 PM Eastern

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time